Citations

Clear

6273 citation(s) found for "To, Andrew".

NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025
Mehren, Margaret von, Kane, John M., Armstrong, Samantha A., Balach, Tessa, Bishop, Andrew J., Buehler, Darya, Carr-Ascher, Janai, Choy, Edwin, Cipriano, Cara, Connolly, Mary, Dann, Amanda, Davis, Elizabeth J., Dry, Sarah, Eulo, Vanessa, Ganjoo, Kristen N., Gonzalez, Ricardo J., Viveiros, Pedro A. Hermida De, Hitchcock, Ying J., Kim, Edward, Lefler, Daniel, Liebner, David, McCarter, Martin, McGarry, Sean V., Mesko, Nathan W., Meyer, Christian, Motamedi, Kambiz, Movva, Sujana, Pappo, Alberto S., Pollack, Seth M., Poppe, Matthew, Riedel, Richard F., Robinson, Steven, Schuetze, Scott M., Sicklick, Jason K., Tseng, William W., Weiss, Mia C., Zimel, Melissa, Hang, Lisa E., Bergman, Mary Anne, Diwan, Zeenat, Pappo, Alberto S. , Riedel, Richard F. , Riedel, Richard F , Mehren, Margaret von, Kane, John M., Armstrong, Samantha A., Balach, Tessa, Bishop, Andrew J., Buehler, Darya, Carr-Ascher, Janai, Choy, Edwin, Cipriano, Cara, Connolly, Mary, Dann, Amanda, Davis, Elizabeth J., Dry, Sarah, Eulo, Vanessa Anne , Ganjoo, Kristen N., Gonzalez, Ricardo J., Viveiros, Pedro A. Hermida De, Hitchcock, Ying J., Kim, Edward, Lefler, Daniel, Liebner, David, McCarter, Martin, McGarry, Sean V., Mesko, Nathan W., Meyer, Christian, Motamedi, Kambiz, Movva, Sujana, Pollack, Seth M., Poppe, Matthew, Robinson, Steven, Schuetze, Scott M., Sicklick, Jason K., Tseng, William W., Weiss, Mia C., Zimel, Melissa, Hang, Lisa E., Bergman, Mary Anne, Diwan, Zeenat

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 17, 2025 | Volume: 23 | Issue: 12 | Pages: 498-506

10.6004/jnccn.2025.0058 | PMID 41671462 Get It

The treatment landscape for soft tissue sarcomas (STS) is evolving constantly. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for STS specific to surgical management and systemic therapy recommendations for various subtypes.
Prospective, randomized dose-escalation trial with proton-based radiation for skull base and cervical spine chondrosarcomas: 30-year outcomes from PROG 85-26
Ioakeim‐Ioannidou, Myrsini, Yeap, Beow Y., Soetan, Z. , Hegazy, Rana , Todary, Engy S. , Tejada, Athena, Adams, Judith E., Kooy, Hanne M., Zieminski, Stephen, Nielsen, G. Petur, Hung, Yin P. , Rosenberg, Andrew , Shankar, Ganesh M. , Cunnane, Mary E. , Chang, Yuh-Shin , Gardner, Paul A. , Giap, Fantine , DeLaney, Thomas F. , Hug, Eugen B., MacDonald, Shannon M. , Packard, Daniel, Hung, Yin P , Kim, Daniel W. , Packard, Daniel George , Hegazy, Rana, Adams, Judith, Depauw, Nicolas , Rosenberg, Andrew, Tobert, Daniel G , Curry, William T. , Coté, Gregory M. , Kelly, Hillary R. , Chen, Yen‐Lin , Liu, Kevin X , Shih, Helen A.

Mayo Clinic

Neuro-Oncology | December 17, 2025 | Volume: 28 | Issue: 4 | Pages: 968-977

10.1093/neuonc/noaf289 | PMID 41414803 Get It

Abstract Background To determine if dose escalation improves outcomes for chondrosarcomas (CHS) of the base of the skull (BOS) and the cervical spine (CS). Methods A prospective, randomized, dose-escalation trial was designed for patients with CHS of the BOS and CS. Patients were randomly assigned to 70 Gy (RBE) or 76 Gy (RBE). The primary endpoint was local failure (LF). Secondary endpoints included overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), and treatment-related toxicities. Results Between 1987 and 2007, 105 patients were randomized, median follow-up was 29.2 years (IQR, 26.7-32.4). Forty-six patients were assigned to 70 Gy (RBE) and 59 were assigned to 76 Gy (RBE). LF at 5-, 10-, and 20 years were 7%, 9%, and 11% for 70 Gy (RBE), and 10%, 15%, and 19% for 76 Gy (RBE) (P = .16). Like LF rates, there was no benefit in dose escalation for OS (P = .28) and CSS (P = .22). Progression-free survival at 5-, 10-, and 20 years was 93%, 89%, and 77% for the low-dose group and 83%, 71%, and 59% for the high-dose group (P = .069). Late RT injury ≥ grade 3 was reported in a total of 19 (18%) patients across both dose levels, with 11% in the low-dose group and 24% in the high-dose group (P = .13). Conclusions This is the first and largest trial of patients with grade I/II BOS and CS CHS evaluating dose escalation for tumor control. Proton-based RT is effective and safe for these tumors, but there is no apparent benefit in dose escalation. Clinical Trial Information NCT00592748.
Navigating the Risks Beyond the Label: Unpacking Global Nutritional Supplement Safety
Wardenaar, Floris C. , Burns, Stephen F. , Campos, Marcus Vinícius Simões de , Chan, Yat C. , Claassen-Smithers, Amanda , Dunshea-Mooij, Christel A.E. , Haddou, Salah Eddine, Hoogervorst, Daan , García, P. , Garthe, Ina, Nugent, Anne P. , Aly, Maged Ossama , Schott, Kinta D. , Sekiguchi, Yasuki , Slater, Gary , Speers, Naomi , Campos, Marcus , Chan, Yat , Dunshea-Mooij, Christel , Jagim, Andrew R , Garcia, Pedro Reinaldo , Nugent, Anne P , Aly, Maged Ossama , Saunders, Bryan , Schott, Kinta D , Sekiguchi, Yasuki , Slater, Gary , Speers, Naomi , Stratton, Matthew T , Aussieker, Thorben , Jagim, Andrew R. , Stratton, Matthew T.

Mayo Clinic

International Journal of Sport Nutrition and Exercise Metabolism | December 17, 2025 | Volume: 36 | Issue: 2 | Pages: 134-166

10.1123/ijsnem.2025-0177 | PMID 41468235 Get It

Nutritional supplement use is common among athletes aiming to enhance performance, recovery, and health. However, variable regulatory frameworks and limited safety oversight create risks for inadvertent doping violations. This article provides a global overview of supplement use, relevant authorities, legislation, and safety measures, with a focus on third-party testing (TPT) as a risk-mitigation strategy. Data from six global regions—Africa, Asia, Australia/New Zealand, Europe, Latin America, and North America—were synthesized from peer-reviewed studies, governmental sources, and regional expert contributions. Reported supplement use ranged from 7% to 100% among athletes (variability within regions), with protein powders, vitamins/minerals, creatine, caffeine, and sports drinks being most prevalent. High-risk products (potential anti-doping rule violations), including certain herbal blends, preworkouts, and weight-management supplements, were reported across all regions. While some countries have robust regulatory systems, most lack harmonized or enforceable safety frameworks. TPT programs, which independently verify products for prohibited substances, remain concentrated in the global northwest (Europe, North America, and Australia/New Zealand); awareness and use of TPT certification vary widely, and even in regions with established systems, athlete adherence is inconsistent. Barriers to low-risk supplement use are limited TPT availability, cost, differences in labeling (including language), and cultural factors. Firsthand experiences and perceptions highlight widespread misconceptions about supplement safety and certification. The authors recommend expanded athlete and team-around-the-athlete education, improved global access to TPT low-risk supplements, and policy initiatives to harmonize safety standards. This work emphasizes the need for coordinated international efforts to protect athlete health and integrity while allowing access to evidence-based supplementation.
APOE, ABCA7 , and RASGEF1C are associated with earlier onset of amyloid deposition from more than 4000 harmonized positron emission tomography images
Castellano, Tonnar , Wang, Ting Chen, Nolan, Emma , Wu, Yiyang , Clifton, Michelle, Janve, Vaibhav A. , Durant, Alaina, Regelson, Alexis, Cody, Karly Alex , Jagust, William, Albert, Marilyn , Resnick, Susan M. , Mayeux, Richard, Initiative, Alzheimer's Disease Neuroimaging, Bennett, David A. , Jager, Philip L. De , Mormino, Elizabeth C. , Koran, Mary Ellen I. , Wang, Ting‐Chen , Bennett, David A. , Koran, Mary Ellen , Cody, Karly A , Wang, Ting Chen, Zhang, Mengna , Harrison, Theresa M. , Engelman, Corinne D. , Johnson, Sterling C. , Sperling, Reisa Anne , Bilgel, Murat , Saykin, Andrew J. , Vardarajan, Badri Narayan , Mayeux, Richard , Initiative, Alzheimer's Disease Neuroimaging, Betthauser, Tobey J. , Schneider, Julie A. , Menon, Vilas , Tosun, Duygu , Archer, Derek B. , Dumitrescu, Logan , Hohman, Timothy J.

Mayo Clinic

Alzheimer's & Dementia | December 13, 2025 | Volume: 21 | Issue: 12 | Pages: No page available

10.1002/alz.71006 | PMID 41388821 Get It

Abstract INTRODUCTION New methods estimate amyloid positivity onset age (EAOA) from amyloid positron emission tomography (PET). We explore the genetics of EAOA to identify molecular factors underlying the earliest Alzheimer's disease (AD) changes. METHODS Harmonized amyloid PET data from 4216 participants were used in genome‐wide survival, tissue‐specific gene expression, and genetic covariance analyses of EAOA. RESULTS Variants in apolipoprotein E ( APOE ), ABCA7 , and RASGEF1C associated with earlier EAOA. APOE ε4/ε4 and ε3/ε4 converted 6.3 and 5 years earlier than ε3/ε3, respectively. ε2 was protective against earlier EAOA. rs4147929, an expression quantitative trait locus for ABCA7 , associated with a 4 year earlier EAOA. This variant was associated with lower brain expression of ABCA7 , which was associated with increased amyloid pathology at autopsy. Multiple immune‐related diseases shared genetic covariance with EAOA. DISCUSSION APOE , ABCA7 , and RASGEF1C associated with earlier EAOA, with supporting evidence from tissue‐specific expression analyses, offering insights into intervenable targets at early stages of AD. Highlights Novel methods estimate how long ago a patient converted to amyloid positivity. Estimating this amyloid clock allows us to determine the onset of the earliest Alzheimer's disease changes. We evaluated what genes influence when someone converts to amyloid positivity. Apolipoprotein E ( APOE ) , ABCA7 , and RASGEF1C associated with earlier age of amyloid positivity. Genetic results were supported by tissue‐specific expression analyses.
Comparing Multislice Projections of MD Simulations with CryoEM Exposes Structural Prediction Errors
Arshad, Mohammed , Lincoff, James , Natale, Andrew M. , Ophus, Colin , Grabe, Michael , Frost, Adam , Moss, Frank R. , Mohammed, Arshad , Natale, Andrew , Mohammed, Arshad

Mayo Clinic

No container title available | December 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.09.693260 | PMID 41415436 Get It

Abstract Cryo-electron microscopy (cryoEM) is a powerful tool for atomic- and molecular-resolution structure determination, while molecular dynamics (MD) simulations are similarly powerful tools for predicting molecular trajectories. Given the challenges in estimating biomolecule dynamics with cryoEM alone, MD simulations are employed to forecast molecular motions and to interpret cryoEM reconstructions. Few methods, however, can evaluate MD predictions directly. Here, we use multislice wave propagation to project sampled snapshots of MD trajectories, either coarse-grained (CG) or all-atom (AA), into simulated cryoEM 3D reconstructions. We compared simulated and experimental images of low- and high-curvature membranes to show that MD simulations qualitatively reflect the fluidity and thus the contrast of biological membranes observed by cryoEM. MD simulations also correctly predicted bilayer dimensions for single component flat bilayers observed in cryoEM images. However, Martini3 CG-MD simulations failed to predict changes in membrane thickness induced by high curvature and with heterogeneous lipid compositions. We pinpointed the misbehavior of polyunsaturated lipid tails and cholesterol in Martini3 simulations as the main error sources contributing to inaccurate bilayer thicknesses. Our comparisons also explain membrane structure discrepancies between cryoEM and small angle X-ray scattering (SAXS). Further testing of MD predictions by direct comparisons between simulated and experimental cryoEM images should lead to the development of more accurate MD force fields. Statement of Significance Molecular dynamics (MD) simulations are frequently employed to predict the dynamics of biological macromolecules and assemblies, but these predictions remain difficult to validate experimentally. Cryo-electron microscopy (cryoEM) can be used to directly image the conformational ensemble of macromolecules, but images of Coulombic potential cannot be easily compared to snapshots of atoms from MD simulations. Here, we show that a physics-based multislice image projection algorithm accurately converts MD trajectories to simulated cryoEM 2D images and 3D reconstructions. Using this approach, we identify consistencies and discrepancies between MD simulations and cryoEM experiments. Notably, coarse-grained MD performs poorly compared to all-atom MD when simulating membranes composed of mixtures of lipids that include cholesterol and polyunsaturated lipids, providing observables for MD force field improvement.
Routine migraine screening as a standard of care for Women's health: A position statement from the American Headache Society
Starling, Amaal J. , Hershey, Andrew D. , O'Brien, Hope L. , Seng, Elizabeth K. , Blum, Adam , Turner, Scott B. , Lipton, Richard B. , Lipton, R.B. , Hershey, Andrew , O'Brien, Hope L , Seng, Elizabeth , Sprouse-Blum, Adam S , Turner, Scott , Schwedt, Todd J. , Ailani, Jessica

Mayo Clinic

Headache: The Journal of Head and Face Pain | December 11, 2025 | Volume: 66 | Issue: 2 | Pages: 511-516

10.1111/head.70023 | PMID 41376343 Get It

Abstract Objectives The aim of this work was to develop an American Headache Society position statement addressing diagnostic screening for migraine among girls and women. Background Despite its high prevalence and substantial negative impacts, migraine is underdiagnosed and undertreated. Diagnostic screening for migraine enables more patients to receive timely, appropriate, and effective management. Methods Development of this position statement followed the rules established by the American Headache Society Guidelines Committee. The published literature was reviewed to determine if migraine meets criteria for when disease screening is justified, to guide recommendations for screening tools, and to determine subpopulation(s) for which migraine screening is indicated. After author consensus was reached, the position statement was reviewed and approved by the American Headache Society Board of Directors. Results Migraine fulfills established criteria for conditions in which screening is appropriate since it is highly prevalent, results in significant morbidity, and exerts substantial economic and social costs. Migraine incidence and prevalence are exceptionally high among girls and women during adolescence and through menopause. Furthermore, there are valid and reliable diagnostic screening methods (e.g., ID Migraine) and effective treatments that reduce migraine symptoms and disease impact. Conclusion Yearly diagnostic screening for migraine should be included as part of women's preventive healthcare services, particularly from adolescence to menopause.
Prevalence and Magnitude Weight Loss Among Collegiate Wrestlers
Dobbs, Ward C. , Horswill, Craig A. , Twohey, Eric , Jones, Margaret T. , Jagim, Andrew R.

Mayo Clinic

Journal of Strength & Conditioning Research | December 10, 2025 | Volume: 40 | Issue: 1 | Pages: 90-97

10.1519/jsc.0000000000005250 | PMID 40961344 Get It

Abstract Jagim, AR, Dobbs, WC, Horswill, CA, Twohey, E, Fields, JB, and Jones, MT. Prevalence and magnitude weight loss among collegiate wrestlers. J Strength Cond Res 40(1): 90–97, 2026—The purpose of this study was to examine the percentage of wrestlers who compete in their minimal weight class (MWC), and the magnitude of weight loss. Data from the 2023–2024 collegiate season were retrospectively analyzed resulting in a sample of 9,638 collegiate male wrestlers from the National Association of Intercollegiate Athletics ( n = 1,904) and all 3 divisions of the National Collegiate Athletics Association ( n = 7,734). All wrestlers completed skinfold assessments for weight certification at the start of the competition season. The lowest recorded weight class (LRW) achieved by each wrestler during the season was also recorded and used to determine magnitude of weight loss. Out of the 4,605 (53.2%) of wrestlers who competed in their MWC, their average amount of weight loss was significantly higher than those who did not compete in their MWC (3.9 ± 2.5 vs. 3.2 ± 2.9 kg.; p < 0.001), yet they had an initial lower body fat percentage (12.7 ± 2.9 vs. 17.5 ± 4.8%; p < 0.001). At the time of weight certification, wrestlers weighed 8.1 ± 4.5 (95% confidence interval (CI): 8.0–8.2; effect size (ES) = 1.8) kg more than their minimal wrestling weight. The LRW was 3.6 ± 2.9 (95% CI: 3.6–3.7; ES = 1.2) kg lower than their weight at the time of weight certification. Given that slightly more than half of the male wrestlers competed in their MWC, coaches and sports practitioners should recognize that not all athletes follow the traditional assumption of cutting to the lowest possible weight class. Importantly, those who did achieve their MWC had lower initial body fat percentages, limiting the amount of weight they could safely lose. This underscores the need for individualized weight management strategies that consider body composition and health implications.
(046) Collagenase Clostridium Histolyticum for Ventral Curvature of the Penis Due to Peyronie’s Disease: Updated Results From a Noninterventional, Retrospective, Multicenter Study
Ziegelmann, Matthew , Cordon, B, Bennett, R, Yafi, FA, Bajic, P, Bennett, NE, Bernie, Helen L. , Mass-Lindenbaum, Marcelo , Hammad, Mustafa , Gumpf, K, Tursi, Jennifer, Hurley, David , Rezakhani, T, Ayad, M, Khera, M, Kava, B., Cordon, Billy H. , Islam, M, Tatem, Andrew J. , Bennett, R, Hammad, M, Andrews, J, Mills, James L.

Mayo Clinic

The Journal of Sexual Medicine | December 9, 2025 | Volume: 22 | Issue: Supplement_4 | Pages: No page available

10.1093/jsxmed/qdaf320.046 Get It

Abstract Introduction While most patients with Peyronie’s disease (PD) present with dorsal or lateral curvature, a significant number have ventral curvature (VC). These patients face limited treatment options, as they were excluded from initial clinical trials of collagenase clostridium histolyticum (CCH) due to safety concerns related to the proximity of the injection site to the urethra. However, urethral involvement is rare, as PD plaques develop in the tunica albuginea rather than the corpus spongiosum surrounding the urethra. Moreover, multiple prospective and retrospective studies have demonstrated favorable outcomes with CCH treatment in men with VC. Objective To evaluate the effectiveness and safety of CCH in men with PD and VC in a multicenter, real-world, retrospective study. Methods This is an ongoing phase 4, multicenter, retrospective review of medical records from 15 US physician sites. Eligible patients consisted of patients who are: age ≥18 years with a diagnosis of VC in PD with a palpable plaque that was treated with CCH from 2014 to the study start date at each site. Patients missing baseline (BL; pretreatment) or final (last measurement within 6 months of final CCH treatment) penile curvature measurements were excluded. Effectiveness endpoints included percentage change in VC from BL to last visit, mean change in VC (in degrees) from BL to last visit, and proportion of patients with ≥30% improvement in VC from BL to last visit. Safety was assessed as proportions of patients reporting treatment-related adverse events (TRAEs) throughout the study period. Results As of April 22, 2025, there were 116 patients with mean (SD) age of 58 (10.3) years who were eligible for analysis. Mean baseline VC decreased from 58 degrees to 37 degrees at last visit (37% improvement). An improvement in VC of ≥30% was seen in 73/116 (63%) of patients, with 81/116 (69.8%) experiencing ≥20% improvement. At least 1 TRAE was reported by 12 (10%) patients. TRAEs were mild-to-moderate in severity in 9 (75%) patients and unknown in 3 patients, with most events (14/17 [82%]) related to injection site reactions. As of the data cut, there were no treatment-related serious or treatment-related severe AEs, no reports of urethral involvement or injury, and no reports of corporal rupture. Conclusions Men with PD who present with ventral curvature represent an underserved patient population. Concerns about potential urethral injury pose a significant barrier to both minimally invasive and surgical treatments, thereby limiting available therapeutic options. These updated results from a multi-institutional real-world clinical cohort align with previous findings, and demonstrate that the clinical effectiveness and safety profile of CCH is consistent with the profile of CCH seen in other clinical presentations of PD. Disclosure Yes, this is sponsored by industry/sponsor: Endo USA, Inc Clarification: Industry initiated, executed and funded study Any of the authors act as a consultant, employee or shareholder of an industry for: Endo USA, Inc.
Differences in Total Daily Energy Expenditure Across Field Sports: A Narrative Review
Skalitzky, Brenen R. , Fields, Jennifer B. , Jones, Margaret T. , Jagim, Andrew R. , Skalitzky, Brenen , Jagim, Andrew R , Fields, Jennifer B , Kerksick, Chad M.

Mayo Clinic

Journal of Functional Morphology and Kinesiology | December 9, 2025 | Volume: 10 | Issue: 4 | Pages: 474

10.3390/jfmk10040474 | PMID 41440795 Get It

Background: Differences in total daily energy expenditure (TDEE) across sports, sex, and skill level support the need for sport- and athlete-specific energy intake recommendations. The purpose of the current review was to examine TDEE and related markers of energy expenditure across field-based team sports. A secondary aim was to evaluate physical activity levels (PAL), calculated as TDEE divided by resting metabolic rate (RMR), and their utility in estimating energy needs within team sports. Methods: The review was limited to studies that included the field-based team sports of rugby or soccer and reported energy expenditure data using doubly labeled water (DLW). A literature review identified 11 studies meeting criteria. Weighted means (Xw) and standard deviations (SDw) were calculated for each variable when pooled across each sport category. Results: Rugby (4417 ± 654 kcal·d−1) had a higher average TDEE than soccer (3157 ± 331 kcal/day; p < 0.001). When normalized to body mass, rTDEE was similar between sports (rugby: 49.5 ± 1.3 kcal·kg−1·day−1; soccer: 49.3 ± 1.8 kcal·kg−1·day−1; p = 0.967). PAL values were significantly higher in rugby (2.2 ± 0.4) compared to soccer (1.7 ± 0.2; p = 0.004). RMR was also greater in rugby (2136 ± 322 kcal·d−1) compared to soccer (1835 ± 208 kcal·d−1; p = 0.04). Conclusions: Rugby athletes exhibited higher TDEE values than soccer athletes, reflecting greater absolute energy demands. However, similar relative TDEE values suggest that differences in body size and composition likely contribute to the observed differences in absolute expenditure. These findings underscore the importance of individualized nutrition strategies within team sports and highlight PAL as a useful metric to contextualize energy requirements.
Catheter Ablation Versus Medical Therapy as First‐Line Treatment for Ventricular Electrical Storm: A Systematic Review and Meta‐Analysis
Sawalha, Khalid , Kusumoto, Fred, Alakchar, Mohammad , Sadeq, Ahmed A., Al-Akchar, Mohammad , Kusumoto, Fred , Goldsweig, Andrew M.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | December 9, 2025 | Volume: 37 | Issue: 2 | Pages: 305-312

10.1111/jce.70222 | PMID 41361845 Get It

ABSTRACT Background Electrical storm (ES) is a life‐threatening manifestation of recurrent ventricular arrhythmia. While anti‐arrhythmic drugs (AADs) have historically been the first‐line treatment, the role of catheter ablation (CA) as an initial therapy in ES remains incompletely defined. This meta‐analysis evaluates the efficacy and safety of radiofrequency CA compared to escalating medical therapy in patients with ES. Methods A systematic search of PubMed, Science Direct, and Cochrane databases was conducted for studies published from 2010 to 2025 that compared CA with medical therapy as first‐line treatment for ES. Outcomes of interest included ES recurrence, ventricular arrhythmia recurrence, in‐hospital mortality, procedural complications, and follow‐up survival. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random‐effects models. Results Six studies encompassing 963 patients (473 CA, 490 medical therapy) were included. The mean age was 67.8 years, and 87.7% were male. The mean left ventricular ejection fraction was 33%, and ischemic cardiomyopathy was present in 77.5% of CA and 72.1% of MT patients. CA reduced the risk of ES recurrence by 71% compared to medical therapy (OR: 0.29; 95% CI: 0.15–0.53; p < 0.001; I ² = 53%). Recurrence of any ventricular arrhythmia, in‐hospital mortality, and long‐term survival were also significantly improved with CA. Conclusion This meta‐analysis suggests that CA is associated with lower ES and VA recurrence and in‐hospital mortality and improved survival compared to medical therapy alone. These findings support consideration of catheter ablation as a first‐line strategy. Larger prospective trials are needed to confirm these findings and guide patient selection.